Quentin Adams1, Karolyn M Hopfensperger2, Yusung Kim3, Xiaodong Wu4, Weiyu Xu5, Hemant Shukla6, James McGee6, Joseph M Caster3, Ryan T Flynn3. 1. Department of Radiation Oncology, University of Iowa, Iowa City, Iowa. Electronic address: quentin-adams@uiowa.edu. 2. Department of Biomedical Engineering, University of Iowa, Iowa City, Iowa. 3. Department of Radiation Oncology, University of Iowa, Iowa City, Iowa. 4. Department of Radiation Oncology, University of Iowa, Iowa City, Iowa; Department of Electrical and Computer Engineering, University of Iowa, Iowa City, Iowa. 5. Department of Electrical and Computer Engineering, University of Iowa, Iowa City, Iowa. 6. OSF Saint Francis Medical Center, Peoria, Illinois.
Abstract
PURPOSE: To compare single-fraction 153Gd-based rotating shield brachytherapy (RSBT) for prostate cancer with conventional 192Ir-based high-dose-rate brachytherapy (HDR-BT) in a planning study that radiobiologically accounts for dose rate and relative biological effectiveness. RSBT was used for planning target volume (PTV) dose escalation without increasing urethral dose for monotherapy, or for urethral sparing without decreasing PTV dose as a boost to external beam radiation therapy. METHODS AND MATERIALS: Twenty-six patients were studied. PTV doses were expressed as equivalent dose delivered in 2 Gy fractions (EQD2), accounting for relative biological effectiveness (1.00 for 192Ir and 1.15 for 153Gd), dose protraction (114-minute repair half-time), and tumor dose response (α/β of 3.41 Gy). HDR-BT dose was prescribed such that 90% of the PTV received 110% of the prescription dose of 19 Gy for dose escalation and 15 Gy for urethral sparing, corresponding to EQD290% values (minimum EQD2 to the hottest 90% of the PTV) of 93.9 GyEQD2 and 60.7 GyEQD2, respectively. Twenty 90.95 GBq 153Gd RSBT sources and one 370 GBq 192Ir HDR-BT source were modeled. RESULTS: For dose escalation with fresh sources, RSBT increased PTV EQD290% by 42.5% ± 8.4% (average ± standard deviation) without increasing urethral D10%, with treatment times of 216.8 ± 28.9 minutes versus 15.1 ± 2.1 minutes. After 1 half-life (240.4 days for 153Gd and 73.8 days for 192Ir), EQD290% increased 20.5% ± 9.1%. For urethral sparing with fresh sources, RSBT decreased urethral D10% by 26.0% ± 3.4% without decreasing PTV EQD290%, with treatment times of 133.6 ± 16.5 minutes versus 12.0 ± 1.7 minutes. After 1 half-life, urethral D10% decreased 20.2% ± 4.8%. CONCLUSIONS: RSBT can increase PTV EQD90% or decrease urethral D10% relative to HDR-BT at the cost of increased treatment time. Source aging reduces RSBT benefit, but RSBT remains theoretically superior to HDR-BT by >20% after 1 half-life has elapsed.
PURPOSE: To compare single-fraction 153Gd-based rotating shield brachytherapy (RSBT) for prostate cancer with conventional 192Ir-based high-dose-rate brachytherapy (HDR-BT) in a planning study that radiobiologically accounts for dose rate and relative biological effectiveness. RSBT was used for planning target volume (PTV) dose escalation without increasing urethral dose for monotherapy, or for urethral sparing without decreasing PTV dose as a boost to external beam radiation therapy. METHODS AND MATERIALS: Twenty-six patients were studied. PTV doses were expressed as equivalent dose delivered in 2 Gy fractions (EQD2), accounting for relative biological effectiveness (1.00 for 192Ir and 1.15 for 153Gd), dose protraction (114-minute repair half-time), and tumor dose response (α/β of 3.41 Gy). HDR-BT dose was prescribed such that 90% of the PTV received 110% of the prescription dose of 19 Gy for dose escalation and 15 Gy for urethral sparing, corresponding to EQD290% values (minimum EQD2 to the hottest 90% of the PTV) of 93.9 GyEQD2 and 60.7 GyEQD2, respectively. Twenty 90.95 GBq 153GdRSBT sources and one 370 GBq 192Ir HDR-BT source were modeled. RESULTS: For dose escalation with fresh sources, RSBT increased PTV EQD290% by 42.5% ± 8.4% (average ± standard deviation) without increasing urethral D10%, with treatment times of 216.8 ± 28.9 minutes versus 15.1 ± 2.1 minutes. After 1 half-life (240.4 days for 153Gd and 73.8 days for 192Ir), EQD290% increased 20.5% ± 9.1%. For urethral sparing with fresh sources, RSBT decreased urethral D10% by 26.0% ± 3.4% without decreasing PTV EQD290%, with treatment times of 133.6 ± 16.5 minutes versus 12.0 ± 1.7 minutes. After 1 half-life, urethral D10% decreased 20.2% ± 4.8%. CONCLUSIONS:RSBT can increase PTV EQD90% or decrease urethral D10% relative to HDR-BT at the cost of increased treatment time. Source aging reduces RSBT benefit, but RSBT remains theoretically superior to HDR-BT by >20% after 1 half-life has elapsed.
Authors: Peter Grimm; Ignace Billiet; David Bostwick; Adam P Dicker; Steven Frank; Jos Immerzeel; Mira Keyes; Patrick Kupelian; W Robert Lee; Stefan Machtens; Jyoti Mayadev; Brian J Moran; Gregory Merrick; Jeremy Millar; Mack Roach; Richard Stock; Katsuto Shinohara; Mark Scholz; Ed Weber; Anthony Zietman; Michael Zelefsky; Jason Wong; Stacy Wentworth; Robyn Vera; Stephen Langley Journal: BJU Int Date: 2012-02 Impact factor: 5.588
Authors: Gerard C Morton; D Andrew Loblaw; Raxa Sankreacha; Andrea Deabreu; Liying Zhang; Alexandre Mamedov; Patrick Cheung; Brian Keller; Cyril Danjoux; Ewa Szumacher; Gillian Thomas Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-14 Impact factor: 7.038
Authors: Alfonso Gomez-Iturriaga; Francisco Casquero; Jose Ignacio Pijoan; Pablo Minguez; Jose Maria Espinosa; Ana Irasarri; Andrea Bueso; Jon Cacicedo; David Buchser; Pedro Bilbao Journal: Radiother Oncol Date: 2017-11-15 Impact factor: 6.280
Authors: Ryan T Flynn; Quentin E Adams; Karolyn M Hopfensperger; Xiaodong Wu; Weiyu Xu; Yusung Kim Journal: Med Phys Date: 2019-05-27 Impact factor: 4.071